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Glioblastoma (GBM) remains incurable with current
standard-of-care therapies. Adoptive T cell transfer
holds the promise to improve outcomes for GBM
patients. We report on the results of the Phase I clinical
study, NCT01109095, administering autologous CMV.
pp65 T cells grafted with a second generation HER2
chimeric antigen receptor (CAR) with a CD28.zeta sig-
naling domain to patients with progressive GBM.
Seventeen CMV-seropositive patients with radiologically
progressive HER2+ GBM were enrolled. The median age
was 49 years (range 11 to 71; 6 children; 11 adults).
Children enrolled had significantly larger tumor volumes at
infusion. A cell product was successfully generated for all
patients from a peripheral blood draw (maximum 90mL). A
median of 67% (range: 46-82) of T cells expressed the HER2
CAR, and exhibited a median 985.5 (range 390 to 1292)
CMV.pp65 reactivity in an IFN-g Elispot assay (SFC/105
T cells). Infusions of 1x106/m2-1x108/m2 were well toler-
ated without severe adverse events or cytokine release syn-
drome. HER2 CMV T cells were detected in the peripheral
blood for up to 12 weeks post infusion, as judged by rtPCR
of a CAR-specific amplicon. Out of 16 evaluable patients,
8 had progressive disease, 8/16 patients had objective
responses: 1 patient had a partial response with a ~62%
reduction in tumor volume lasting 8 months, 7 patients had
stable disease for more than 6 weeks (of these 5 were dur-
able >10 weeks) and 3 subjects are currently with a follow
up 24 to >30 months, after T cell infusion. The median sur-
vival was 11.6 months from infusion and 24.8 months from
diagnosis. The median survival for adults was 30 months
from diagnosis.
We conclude that systemically administered HER2
CAR CMV bispecific T cells are safe. A durable clinical
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